Retour vers les projets


How to develop a therapy against cancer

This project is presented by Dominique Bagnard, Senior Lecturer – Laboratory MN3T (The Microenvironmental Niche in Tumorigenesis and Targeted Therapy). The project is about the validation of a new anti-tumor peptide compound (MTP-NRP1). The investment granted by Conectus will allow the research team to realize studies for the production of GMP quality (Good Manufacturing Practice) peptide and to find the best treatment combination to refine the market positioning of therapies targeting cancer.


At the end of this maturation stage Dominique Bagnard whishes to create a start-up in order to commercialize this technology.


Investment: 304 290€ over a period of 18 months